sulfadoxine + pyrimethamine + amodiaquine

This drug is a fixed-dose or co-packaged combination of three antimalarial agents—sulfadoxine (a sulfonamide antibiotic), pyrimethamine (a dihydrofolate reductase inhibitor), and amodiaquine (a 4-aminoquinoline derivative). It is primarily used for the prevention and treatment of malaria caused by *Plasmodium falciparum*, especially in regions with high seasonal transmission. The combination acts synergistically to inhibit folate synthesis at two different steps in the parasite's metabolic pathway (via sulfadoxine and pyrimethamine) and disrupts heme detoxification within the parasite's food vacuole (via amodiaquine). This triple therapy is recommended by the World Health Organization for seasonal malaria chemoprevention (SMC) in children aged 3–59 months living in areas with highly seasonal malaria transmission, particularly across the Sahel sub-region of Africa. Clinical trials have demonstrated that this combination significantly reduces clinical episodes of malaria, severe cases, mortality rates, and anemia among children during peak transmission seasons[1][7][8]. The use of all three drugs together increases efficacy compared to monotherapy or dual therapy and helps delay resistance development[2][4].

Brand names

MA147MA-147MA 147

Other names

sulfadoxine/pyrimethamine-amodiaquineSP+AQAQ+SPamodiaquine + sulfadoxine + pyrimethamine